Geode Capital Management’s AbbVie ABBV Stock Holding History

Geode Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.1B	Buy	46,737,581 +2,107,601	+5%	+$468M	0.63%	19
2025 Q4	$10.2B	Buy	44,629,980 +4,190,487	+10%	+$955M	0.63%	18
2025 Q3	$9.33B	Buy	40,439,493 +1,261,142	+3%	+$257M	0.6%	23
2025 Q2	$7.24B	Buy	39,178,351 +924,761	+2%	+$172M	0.51%	23
2025 Q1	$7.99B	Buy	38,253,590 +1,108,657	+3%	+$216M	0.63%	23
2024 Q4	$6.59B	Buy	37,144,933 +983,888	+3%	+$181M	0.51%	24
2024 Q3	$7.12B	Sell	36,161,045 -520,705	-1%	-$97.2M	0.58%	21
2024 Q2	$6.28B	Sell	36,681,750 -812,903	-2%	-$135M	0.55%	22
2024 Q1	$6.81B	Buy	37,494,653 +477,167	+1%	+$82.2M	0.63%	21
2023 Q4	$5.72B	Buy	37,017,486 +810,314	+2%	+$118M	0.6%	23
2023 Q3	$5.39B	Buy	36,207,172 +1,254,234	+4%	+$184M	0.64%	22
2023 Q2	$4.7B	Buy	34,952,938 +907,917	+3%	+$133M	0.55%	25
2023 Q1	$5.41B	Buy	34,045,021 +292,512	+0.9%	+$44.7M	0.7%	19
2022 Q4	$5.45B	Sell	33,752,509 -77,992	-0.2%	-$12M	0.76%	19
2022 Q3	$4.54B	Buy	33,830,501 +3,749,074	+12%	+$538M	0.69%	21
2022 Q2	$4.6B	Buy	30,081,427 +1,361,176	+5%	+$208M	0.67%	22
2022 Q1	$4.64B	Buy	28,720,251 +201,305	+0.7%	+$29.2M	0.58%	21
2021 Q4	$3.85B	Buy	28,518,946 +758,354	+3%	+$89.6M	0.46%	35
2021 Q3	$2.99B	Buy	27,760,592 +515,643	+2%	+$58.9M	0.4%	46
2021 Q2	$3.06B	Buy	27,244,949 +12,350	+0%	+$1.39M	0.42%	39
2021 Q1	$2.94B	Buy	27,232,599 +550,676	+2%	+$58.9M	0.45%	36
2020 Q4	$2.85B	Buy	26,681,923 +546,851	+2%	+$52.6M	0.48%	33
2020 Q3	$2.28B	Sell	26,135,072 -2,823,520	-10%	-$266M	0.45%	39
2020 Q2	$2.84B	Buy	28,958,592 +3,185,087	+12%	+$280M	0.61%	27
2020 Q1	$1.96B	Buy	25,773,505 +1,344,728	+6%	+$115M	0.51%	34
2019 Q4	$2.16B	Buy	24,428,777 +681,783	+3%	+$56.6M	0.45%	40
2019 Q3	$1.8B	Buy	23,746,994 +1,524,799	+7%	+$105M	0.42%	43
2019 Q2	$1.61B	Buy	22,222,195 +817,407	+4%	+$64.2M	0.39%	46
2019 Q1	$1.72B	Buy	21,404,788 +3,822,261	+22%	+$313M	0.45%	39
2018 Q4	$1.62B	Buy	17,582,527 +880,288	+5%	+$77.4M	0.5%	33
2018 Q3	$1.58B	Buy	16,702,239 +36,620	+0.2%	+$3.47M	0.44%	38
2018 Q2	$1.54B	Sell	16,665,619 -494,832	-3%	-$48.3M	0.47%	35
2018 Q1	$1.62B	Buy	17,160,451 +1,117,600	+7%	+$123M	0.53%	33
2017 Q4	$1.55B	Buy	16,042,851 +697,191	+5%	+$65.7M	0.53%	35
2017 Q3	$1.36B	Buy	15,345,660 +321,142	+2%	+$24.4M	0.5%	38
2017 Q2	$1.09B	Buy	15,024,518 +115,467	+0.8%	+$7.76M	0.43%	40
2017 Q1	$970M	Buy	14,909,051 +918,685	+7%	+$57.8M	0.4%	43
2016 Q4	$875M	Buy	13,990,366 +575,380	+4%	+$35.1M	0.41%	45
2016 Q3	$845M	Buy	13,414,986 +556,563	+4%	+$36M	0.43%	43
2016 Q2	$795M	Sell	12,858,423 -192,758	-1%	-$11.7M	0.43%	43
2016 Q1	$744K	Buy	13,051,181 +93,719	+0.7%	+$5.22M	0.39%	47
2015 Q4	$766M	Sell	12,957,462 -151,998	-1%	-$8.75M	0.44%	44
2015 Q3	$712M	Sell	13,109,460 -443,361	-3%	-$28.9M	0.43%	44
2015 Q2	$909M	Buy	13,552,821 +900,542	+7%	+$58.8M	0.52%	36
2015 Q1	$740M	Buy	12,652,279 +465,805	+4%	+$28.1M	0.42%	48
2014 Q4	$796M	Buy	12,186,474 +452,248	+4%	+$28.5M	0.47%	40
2014 Q3	$677M	Sell	11,734,226 -46,771	-0.4%	-$2.6M	0.44%	39
2014 Q2	$665M	Sell	11,780,997 -81,102	-0.7%	-$4.25M	0.43%	41
2014 Q1	$609M	Buy	11,862,099 +88,301	+0.7%	+$4.46M	0.41%	46
2013 Q4	$622M	Buy	11,773,798 +432,980	+4%	+$21.3M	0.43%	44
2013 Q3	$507M	Buy	11,340,818 +352,747	+3%	+$15.6M	0.41%	45
2013 Q2	$454M	Buy	+10,988,071	New	+$481M	0.4%	49

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management's ABBV Position: Q1 2026 in Review

Geode Capital Management increased its AbbVie (ABBV) stake by 4.7% in Q1 2026, buying an estimated $468M and bringing the position to 46,737,581 shares worth $10.1B. The position accounts for 0.63% of the portfolio, ranked #19.

Geode Capital Management first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $10.2B in Q4 2025. 4,081 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Geode Capital Management held 46,737,581 shares of AbbVie worth $10.1B as of Q1 2026.
Geode Capital Management bought 2,107,601 AbbVie shares in Q1 2026, an estimated $468M.
AbbVie made up 0.63% of Geode Capital Management's portfolio in Q1 2026, its #19 holding.
Geode Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Geode Capital Management's AbbVie position peaked at $10.2B in Q4 2025.
4,081 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.